Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer

R. B. Costa, G. Kurra, L. Greenberg, C. E. Geyer

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Background: Trastuzumab-based adjuvant therapy has become the standard of care for human epidermal growth factor receptor-2 (HER2)-positive early breast cancer (EBC). Both anthracycline- and non-anthracycline-containing trastuzumab regimens are approved in the United States, but cardiotoxicity is increased with anthracycline-containing regimens. Design: This paper reviews published and reported efficacy and cardiac safety data from the adjuvant trastuzumab trials [National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31/North Central Cancer Treatment Group (NCCTG) N9831, Breast Cancer International Research Group (BCIRG) 006, Herceptin Adjuvant (HERA), FinHer, and Programme Adjuvant Cancer Sein (PACS) 04]. Results: The addition of trastuzumab to adjuvant chemotherapy significantly improved disease-free survival (from 24% to 58%) in five of the six trials. Overall survival was significantly improved (23%-35%) in the large trials. In NSABP B-31/NCCTG N9831, 5.0%-6.6% of patients who received doxorubicin and cyclophosphamide (AC) were unable to receive trastuzumab. Cardiac event rate was highest in the anthracycline-containing trastuzumab arms (1.9%-3.8%) and lowest with the regimen of docetaxel, carboplatin, and trastuzumab (TCH) (0.4%). Conclusions: Incorporation of trastuzumab into anthracycline and non-anthracycline adjuvant chemotherapy regimens has substantially improved outcomes in HER2-postive EBC. The TCH regimen has the lowest rates of cardiac dysfunction, but uncertainty exists regarding the relative efficacy of TCH compared with anthracycline-containing trastuzumab regimens. Cardiac risk factor assessment can aid in selection of trastuzumab-based adjuvant therapy regimens.

Original languageEnglish (US)
Pages (from-to)2153-2160
Number of pages8
JournalAnnals of Oncology
Volume21
Issue number11
DOIs
StatePublished - Nov 2010

Fingerprint

Breast Neoplasms
Safety
Drug Therapy
Anthracyclines
docetaxel
Adjuvant Chemotherapy
Breast
human ERBB2 protein
Trastuzumab
Neoplasms
Carboplatin
Therapeutics
Standard of Care
Doxorubicin
Cyclophosphamide
Disease-Free Survival
Uncertainty
Arm
Survival
Research

Keywords

  • Adjuvant
  • Anthracyclines
  • Breast cancer
  • Cardiac dysfunction
  • HER2
  • Trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. / Costa, R. B.; Kurra, G.; Greenberg, L.; Geyer, C. E.

In: Annals of Oncology, Vol. 21, No. 11, 11.2010, p. 2153-2160.

Research output: Contribution to journalArticle

Costa, R. B. ; Kurra, G. ; Greenberg, L. ; Geyer, C. E. / Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. In: Annals of Oncology. 2010 ; Vol. 21, No. 11. pp. 2153-2160.
@article{e8e372b5f1cb4827a9d915b066922e65,
title = "Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer",
abstract = "Background: Trastuzumab-based adjuvant therapy has become the standard of care for human epidermal growth factor receptor-2 (HER2)-positive early breast cancer (EBC). Both anthracycline- and non-anthracycline-containing trastuzumab regimens are approved in the United States, but cardiotoxicity is increased with anthracycline-containing regimens. Design: This paper reviews published and reported efficacy and cardiac safety data from the adjuvant trastuzumab trials [National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31/North Central Cancer Treatment Group (NCCTG) N9831, Breast Cancer International Research Group (BCIRG) 006, Herceptin Adjuvant (HERA), FinHer, and Programme Adjuvant Cancer Sein (PACS) 04]. Results: The addition of trastuzumab to adjuvant chemotherapy significantly improved disease-free survival (from 24{\%} to 58{\%}) in five of the six trials. Overall survival was significantly improved (23{\%}-35{\%}) in the large trials. In NSABP B-31/NCCTG N9831, 5.0{\%}-6.6{\%} of patients who received doxorubicin and cyclophosphamide (AC) were unable to receive trastuzumab. Cardiac event rate was highest in the anthracycline-containing trastuzumab arms (1.9{\%}-3.8{\%}) and lowest with the regimen of docetaxel, carboplatin, and trastuzumab (TCH) (0.4{\%}). Conclusions: Incorporation of trastuzumab into anthracycline and non-anthracycline adjuvant chemotherapy regimens has substantially improved outcomes in HER2-postive EBC. The TCH regimen has the lowest rates of cardiac dysfunction, but uncertainty exists regarding the relative efficacy of TCH compared with anthracycline-containing trastuzumab regimens. Cardiac risk factor assessment can aid in selection of trastuzumab-based adjuvant therapy regimens.",
keywords = "Adjuvant, Anthracyclines, Breast cancer, Cardiac dysfunction, HER2, Trastuzumab",
author = "Costa, {R. B.} and G. Kurra and L. Greenberg and Geyer, {C. E.}",
year = "2010",
month = "11",
doi = "10.1093/annonc/mdq096",
language = "English (US)",
volume = "21",
pages = "2153--2160",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer

AU - Costa, R. B.

AU - Kurra, G.

AU - Greenberg, L.

AU - Geyer, C. E.

PY - 2010/11

Y1 - 2010/11

N2 - Background: Trastuzumab-based adjuvant therapy has become the standard of care for human epidermal growth factor receptor-2 (HER2)-positive early breast cancer (EBC). Both anthracycline- and non-anthracycline-containing trastuzumab regimens are approved in the United States, but cardiotoxicity is increased with anthracycline-containing regimens. Design: This paper reviews published and reported efficacy and cardiac safety data from the adjuvant trastuzumab trials [National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31/North Central Cancer Treatment Group (NCCTG) N9831, Breast Cancer International Research Group (BCIRG) 006, Herceptin Adjuvant (HERA), FinHer, and Programme Adjuvant Cancer Sein (PACS) 04]. Results: The addition of trastuzumab to adjuvant chemotherapy significantly improved disease-free survival (from 24% to 58%) in five of the six trials. Overall survival was significantly improved (23%-35%) in the large trials. In NSABP B-31/NCCTG N9831, 5.0%-6.6% of patients who received doxorubicin and cyclophosphamide (AC) were unable to receive trastuzumab. Cardiac event rate was highest in the anthracycline-containing trastuzumab arms (1.9%-3.8%) and lowest with the regimen of docetaxel, carboplatin, and trastuzumab (TCH) (0.4%). Conclusions: Incorporation of trastuzumab into anthracycline and non-anthracycline adjuvant chemotherapy regimens has substantially improved outcomes in HER2-postive EBC. The TCH regimen has the lowest rates of cardiac dysfunction, but uncertainty exists regarding the relative efficacy of TCH compared with anthracycline-containing trastuzumab regimens. Cardiac risk factor assessment can aid in selection of trastuzumab-based adjuvant therapy regimens.

AB - Background: Trastuzumab-based adjuvant therapy has become the standard of care for human epidermal growth factor receptor-2 (HER2)-positive early breast cancer (EBC). Both anthracycline- and non-anthracycline-containing trastuzumab regimens are approved in the United States, but cardiotoxicity is increased with anthracycline-containing regimens. Design: This paper reviews published and reported efficacy and cardiac safety data from the adjuvant trastuzumab trials [National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31/North Central Cancer Treatment Group (NCCTG) N9831, Breast Cancer International Research Group (BCIRG) 006, Herceptin Adjuvant (HERA), FinHer, and Programme Adjuvant Cancer Sein (PACS) 04]. Results: The addition of trastuzumab to adjuvant chemotherapy significantly improved disease-free survival (from 24% to 58%) in five of the six trials. Overall survival was significantly improved (23%-35%) in the large trials. In NSABP B-31/NCCTG N9831, 5.0%-6.6% of patients who received doxorubicin and cyclophosphamide (AC) were unable to receive trastuzumab. Cardiac event rate was highest in the anthracycline-containing trastuzumab arms (1.9%-3.8%) and lowest with the regimen of docetaxel, carboplatin, and trastuzumab (TCH) (0.4%). Conclusions: Incorporation of trastuzumab into anthracycline and non-anthracycline adjuvant chemotherapy regimens has substantially improved outcomes in HER2-postive EBC. The TCH regimen has the lowest rates of cardiac dysfunction, but uncertainty exists regarding the relative efficacy of TCH compared with anthracycline-containing trastuzumab regimens. Cardiac risk factor assessment can aid in selection of trastuzumab-based adjuvant therapy regimens.

KW - Adjuvant

KW - Anthracyclines

KW - Breast cancer

KW - Cardiac dysfunction

KW - HER2

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=77958453259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958453259&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdq096

DO - 10.1093/annonc/mdq096

M3 - Article

C2 - 20351072

AN - SCOPUS:77958453259

VL - 21

SP - 2153

EP - 2160

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 11

ER -